vs
Side-by-side financial comparison of NexPoint Residential Trust, Inc. (NXRT) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $62.1M, roughly 1.2× NexPoint Residential Trust, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -2.7%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -4.1%).
NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
NXRT vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $75.5M |
| Net Profit | — | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 8.4% | 22.7% |
| Net Margin | — | — |
| Revenue YoY | -2.7% | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $75.5M | ||
| Q3 25 | $62.8M | $54.5M | ||
| Q2 25 | $63.1M | $52.4M | ||
| Q1 25 | $63.2M | $46.0M | ||
| Q4 24 | $63.8M | $59.1M | ||
| Q3 24 | $64.1M | $80.5M | ||
| Q2 24 | $64.2M | $47.1M | ||
| Q1 24 | $67.6M | $43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-7.8M | $8.8M | ||
| Q2 25 | $-7.0M | $5.9M | ||
| Q1 25 | $-6.9M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.9M | $20.3M | ||
| Q2 24 | $10.6M | $-4.5M | ||
| Q1 24 | $26.3M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 8.4% | 22.7% | ||
| Q3 25 | 11.8% | 17.6% | ||
| Q2 25 | 12.5% | 12.7% | ||
| Q1 25 | 11.7% | 8.7% | ||
| Q4 24 | 18.0% | 22.6% | ||
| Q3 24 | 8.7% | 27.4% | ||
| Q2 24 | 39.7% | -4.6% | ||
| Q1 24 | 60.7% | -5.3% |
| Q4 25 | — | — | ||
| Q3 25 | -12.4% | 16.2% | ||
| Q2 25 | -11.1% | 11.2% | ||
| Q1 25 | -10.9% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -13.8% | 25.2% | ||
| Q2 24 | 16.5% | -9.6% | ||
| Q1 24 | 38.9% | -11.0% |
| Q4 25 | — | $0.26 | ||
| Q3 25 | $-0.31 | $0.17 | ||
| Q2 25 | $-0.28 | $0.12 | ||
| Q1 25 | $-0.27 | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $-0.35 | $0.41 | ||
| Q2 24 | $0.40 | $-0.09 | ||
| Q1 24 | $1.00 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $97.5M |
| Total DebtLower is stronger | $1.6B | $22.7M |
| Stockholders' EquityBook value | $295.5M | $130.3M |
| Total Assets | $1.9B | $216.3M |
| Debt / EquityLower = less leverage | 5.39× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $97.5M | ||
| Q3 25 | $10.8M | $94.4M | ||
| Q2 25 | $13.6M | $96.0M | ||
| Q1 25 | $23.7M | $93.2M | ||
| Q4 24 | $23.1M | $101.0M | ||
| Q3 24 | $17.4M | $96.7M | ||
| Q2 24 | $21.3M | $96.8M | ||
| Q1 24 | $37.2M | $107.2M |
| Q4 25 | $1.6B | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | $1.5B | $102.0M |
| Q4 25 | $295.5M | $130.3M | ||
| Q3 25 | $322.9M | $115.3M | ||
| Q2 25 | $347.9M | $104.7M | ||
| Q1 25 | $379.9M | $97.1M | ||
| Q4 24 | $410.4M | $92.1M | ||
| Q3 24 | $447.1M | $71.1M | ||
| Q2 24 | $491.1M | $48.5M | ||
| Q1 24 | $512.8M | $51.0M |
| Q4 25 | $1.9B | $216.3M | ||
| Q3 25 | $1.8B | $202.9M | ||
| Q2 25 | $1.9B | $194.9M | ||
| Q1 25 | $1.9B | $196.2M | ||
| Q4 24 | $1.9B | $213.3M | ||
| Q3 24 | $2.0B | $220.7M | ||
| Q2 24 | $2.0B | $205.0M | ||
| Q1 24 | $2.0B | $214.1M |
| Q4 25 | 5.39× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | 2.92× | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | $14.4M | ||
| Q3 25 | $29.3M | $9.7M | ||
| Q2 25 | $19.9M | $14.1M | ||
| Q1 25 | $28.3M | $3.6M | ||
| Q4 24 | $73.6M | $15.6M | ||
| Q3 24 | $27.8M | $11.0M | ||
| Q2 24 | $19.7M | $1.0M | ||
| Q1 24 | $19.7M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
